Minerva Neurosciences Current Ratio Growth & History (NERV)
Minerva Neurosciences's current ratio was 36.28 for fiscal 2025.
View full Minerva Neurosciences company overviewMinerva Neurosciences annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 36.28 | 28.43 | +362.18% |
| 2024 | 2024-12-31 | 7.85 | −4.72 | −37.57% |
| 2023 | 2023-12-31 | 12.57 | −16.58 | −56.87% |
| 2022 | 2022-12-31 | 29.15 | 7.09 | +32.12% |
| 2021 | 2021-12-31 | 22.07 | 13.38 | +154.12% |
| 2020 | 2020-12-31 | 8.68 | 1.57 | +22.11% |
| 2019 | 2019-12-31 | 7.11 | −17.83 | −71.49% |
| 2018 | 2018-12-31 | 24.94 | 6.00 | +31.66% |
| 2017 | 2017-12-31 | 18.94 | 10.29 | +118.79% |
| 2016 | 2016-12-31 | 8.66 | 2.36 | +37.58% |
| 2015 | 2015-12-31 | 6.29 | 0.78 | +14.22% |
| 2014 | 2014-12-31 | 5.51 | 4.22 | +326.04% |
| 2013 | 2013-12-31 | 1.29 | — | — |
Minerva Neurosciences quarterly current ratio
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 20.14 | 14.00 | +227.65% |
| Q1 2026 | 2026-03-31 | 17.65 | 8.44 | +91.72% |
| Q4 2025 | 2025-12-31 | 36.28 | 28.43 | +362.18% |
| Q3 2025 | 2025-09-30 | 4.87 | −1.36 | −21.81% |
| Q2 2025 | 2025-06-30 | 6.15 | −1.32 | −17.72% |
| Q1 2025 | 2025-03-31 | 9.21 | −3.38 | −26.84% |
| Q4 2024 | 2024-12-31 | 7.85 | −4.72 | −37.57% |
| Q3 2024 | 2024-09-30 | 6.23 | −8.17 | −56.72% |
| Q2 2024 | 2024-06-30 | 7.47 | −19.90 | −72.70% |
| Q1 2024 | 2024-03-31 | 12.58 | −2.08 | −14.17% |
| Q4 2023 | 2023-12-31 | 12.57 | −16.58 | −56.87% |
| Q3 2023 | 2023-09-30 | 14.40 | −6.01 | −29.47% |
| Q2 2023 | 2023-06-30 | 27.37 | 12.70 | +86.49% |
| Q1 2023 | 2023-03-31 | 14.66 | −2.49 | −14.52% |
| Q4 2022 | 2022-12-31 | 29.15 | 7.09 | +32.12% |
| Q3 2022 | 2022-09-30 | 20.41 | −1.46 | −6.70% |
| Q2 2022 | 2022-06-30 | 14.68 | −2.25 | −13.28% |
| Q1 2022 | 2022-03-31 | 17.15 | −7.17 | −29.49% |
| Q4 2021 | 2021-12-31 | 22.07 | 13.38 | +154.12% |
| Q3 2021 | 2021-09-30 | 21.88 | 15.39 | +237.26% |
| Q2 2021 | 2021-06-30 | 16.93 | 12.08 | +249.12% |
| Q1 2021 | 2021-03-31 | 24.32 | 18.92 | +350.07% |
| Q4 2020 | 2020-12-31 | 8.68 | 1.57 | +22.11% |
| Q3 2020 | 2020-09-30 | 6.49 | 0.28 | +4.53% |
| Q2 2020 | 2020-06-30 | 4.85 | −4.49 | −48.07% |
| Q1 2020 | 2020-03-31 | 5.40 | −6.23 | −53.56% |
| Q4 2019 | 2019-12-31 | 7.11 | −17.83 | −71.49% |
| Q3 2019 | 2019-09-30 | 6.21 | −20.00 | −76.32% |
| Q2 2019 | 2019-06-30 | 9.34 | −12.95 | −58.11% |
| Q1 2019 | 2019-03-31 | 11.64 | −4.20 | −26.53% |
| Q4 2018 | 2018-12-31 | 24.94 | 6.00 | +31.66% |
| Q3 2018 | 2018-09-30 | 26.20 | 10.82 | +70.40% |
| Q2 2018 | 2018-06-30 | 22.28 | 16.93 | +316.35% |
| Q1 2018 | 2018-03-31 | 15.84 | 9.20 | +138.49% |
| Q4 2017 | 2017-12-31 | 18.94 | 10.29 | +118.79% |
| Q3 2017 | 2017-09-30 | 15.38 | 6.20 | +67.62% |
| Q2 2017 | 2017-06-30 | 5.35 | −10.26 | −65.73% |
| Q1 2017 | 2017-03-31 | 6.64 | 0.14 | +2.08% |
| Q4 2016 | 2016-12-31 | 8.66 | 2.36 | +37.58% |
| Q3 2016 | 2016-09-30 | 9.17 | −2.91 | −24.11% |
| Q2 2016 | 2016-06-30 | 15.62 | 6.23 | +66.41% |
| Q1 2016 | 2016-03-31 | 6.51 | −5.41 | −45.41% |
| Q4 2015 | 2015-12-31 | 6.29 | 0.78 | +14.22% |
| Q3 2015 | 2015-09-30 | 12.09 | 4.47 | +58.63% |
| Q2 2015 | 2015-06-30 | 9.38 | 9.33 | +18281.89% |
| Q1 2015 | 2015-03-31 | 11.92 | — | — |
| Q4 2014 | 2014-12-31 | 5.51 | 4.22 | +326.04% |
| Q3 2014 | 2014-09-30 | 7.62 | — | — |
| Q2 2014 | 2014-06-30 | 0.05 | — | — |
| Q4 2013 | 2013-12-31 | 1.29 | — | — |
Minerva Neurosciences current ratio trends
Over the last five fiscal years, Minerva Neurosciences's current ratio increased from 8.68 to 36.28, a change of 27.60. The latest reported quarter, Q2 2026, shows 20.14.
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Minerva Neurosciences source filings ↗